Junshi Biotech (688180.SH): Application for marketing of a new drug with rocoqibizumab injection was accepted

Zhitong Finance App News, Junshi Biotech (688180.SH) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the State Drug Administration. The new drug marketing application for the company's product, rocoqibizumab injection (recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005) for the treatment of adult patients with moderate to severe plaque psoriasis suitable for systematic treatment or phototherapy was accepted.

Rokocibimab is a specific anti-IL-17A monoclonal antibody independently developed by the company. IL (interleukin) -17A is a multi-potent cytokine, and its secretion disorder is closely related to the occurrence and development of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By binding to IL-17A with high affinity and selectively blocking the binding of IL-17A to its receptor IL-17RA/IL-17RC, rococcibimab blocks the activation of downstream signaling pathways and the release of inflammatory factors, and can effectively relieve symptoms of autoimmune diseases. As of the announcement disclosure date, with the exception of this new drug marketing application, all participants in the phase II clinical study of rocoqibimab for the treatment of active ankylosing spondylitis had completed treatment and entered a safe follow-up period.